Holen Sie sich die Stockscreener-App
95.77
1.06%
-1.03
Handel nachbörslich:
95.77
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$96.80
Offen:
$95.96
24-Stunden-Volumen:
2.44M
Relative Volume:
1.84
Marktkapitalisierung:
$47.37B
Einnahmen:
$9.91B
Nettoeinkommen (Verlust:
$1.02B
KGV:
46.72
EPS:
2.05
Netto-Cashflow:
$665.00M
1W Leistung:
+5.75%
1M Leistung:
+4.13%
6M Leistung:
-3.88%
1J Leistung:
+14.98%
1-Tages-Spanne:
$95.59
$96.38
1-Wochen-Bereich:
$90.64
$97.40
52-Wochen-Spanne:
$77.54
$101.10
Alcon Inc Stock (ALC) Company Profile
Vergleichen Sie ALC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
95.77 | 47.37B | 9.91B | 1.02B | 665.00M | 2.05 |
|
ISRG
Intuitive Surgical Inc
|
491.84 | 181.97B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
227.50 | 66.11B | 20.64B | 1.73B | 2.94B | 6.02 |
|
RMD
Resmed Inc
|
219.94 | 32.31B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
33.75 | 17.31B | 17.28B | 108.00M | 391.00M | 0.20 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-24 | Bestätigt | Needham | Buy |
| 2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
Taxation With Representation: Norton Rose, Latham, Ashurst - Law360
Alcon stock price target raised to $110 at Needham - Investing.com India
Alcon (ALC) Soars 6.0%: Is Further Upside Left in the Stock? - Nasdaq
Mizuho lifts Alcon stock price target to $120, maintains Outperform - Investing.com
Mizuho lifts Alcon stock price target to $120, maintains Outperform By Investing.com - Investing.com UK
Jefferies raises Alcon stock price target to $115, maintains Buy - Investing.com India
Jefferies raises Alcon stock price target to $115, maintains Buy By Investing.com - Investing.com UK
Citi maintains Alcon stock Buy rating, CHF99.00 target - Investing.com India
Citi maintains Alcon stock Buy rating, CHF99.00 target By Investing.com - Investing.com UK
Alcon (VTX:ALC) ascends 4.7% this week, taking five-year gains to 80% - Yahoo Finance
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Cell Therapy for Corneal Endothelial Disease - Vision Monday
Alcon Inc’s Acquisition of LENSAR Inc - Global Legal Chronicle
Alcon's Future Looks Fruitful as New Innovation and Commercial Execution Spark Market Outperformance - Morningstar
All eyes on ophthalmic cell therapy space as Alcon takes majority stake in Aurion - FirstWord Pharma
Alcon buys majority stake in IPO-seeking cell therapy startup Aurion - BioPharma Dive
Alcon claims control of cell therapy firm Aurion - pharmaphorum
Alcon acquires majority interest in Aurion Biotech - Ophthalmology Times
Alcon secures majority stake in Aurion, deposes CEO - PharmaLive
Related Content: Alcon to Acquire LENSAR | Business | Mar 2025 - Photonics.com
Alcon to buy Lensar in deal worth up to $430M - The Business Journals
Alcon to Acquire LENSAR | Business | Mar 2025 - Photonics.com
Alcon upgraded at BofA Securities to Buy on earnings growth potential - MSN
Alcon acquires majority interest in Aurion Biotech to advance first-ever corneal cell therapy candidate - BSA bureau
Aurion CEO is out as Alcon takes majority stake in cell therapy startup - Endpoints News
Alcon acquires majority stake in Aurion Biotech By Investing.com - Investing.com South Africa
Alcon buys majority stake in Aurion Biotech (ALC:NYSE) - Seeking Alpha
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease - Sharewise
Alcon acquires majority stake in Aurion Biotech - Investing.com
Alcon Acquires Majority Interest In Aurion Biotech, Inc. To Advance Innovative Cell Therapy For Corneal Endothelial Disease - Marketscreener.com
Alcon signs merger agreement to acquire Lensar - MSN
Stifel maintains Alcon stock Buy rating, $100 price target By Investing.com - Investing.com Australia
Stifel maintains Alcon stock Buy rating with $100 target By Investing.com - Investing.com Australia
Bernstein maintains Alcon Outperform rating, $110.50 target - Investing.com
Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval - MSN
Alcon Gets EU Nod for Clareon Vivity Intraocular Lens - MPO-mag
Bank of America Upgrades Alcon (ALC) Stock Rating Amid Growth Pr - GuruFocus.com
HSBC and BofA have differing views on Alcon ahead of product launches - TradingView
ALC Stock Rises Following the Merger Agreement With LENSAR - TradingView
Stifel maintains Alcon stock Buy rating, $100 price target - Investing.com India
BofA raises Alcon stock rating, boosts target to CHF96 By Investing.com - Investing.com South Africa
Alcon agrees to purchase LENSAR - Ophthalmology Times
BofA raises Alcon stock rating, boosts target to CHF96 - Investing.com India
Switzerland: Alcon agrees acquisition of Lensar for up to US$430m - Investors in Healthcare
Alcon Gets CE Mark for Clareon Vivity Intraocular Lens - Marketscreener.com
Alcon to Begin Commercial Rollout of Vivity Lens in Europe by Q2 - Marketscreener.com
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities - Business Wire
Alcon Agrees to Acquire Lensar, Inc. for Up to $430 Million - Vision Monday
BTIG cuts LENSAR stock rating post Alcon acquisition deal - Investing.com India
BTIG cuts LENSAR stock rating post Alcon acquisition deal By Investing.com - Investing.com Australia
Latham & Watkins Represents LENSAR, Inc. in Acquisition by Alcon - Latham & Watkins LLP
Alcon to Acquire LENSAR in $430M Deal - USA Herald
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.20%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):